陈忠,马根山,冯毅,罗丹,沈成兴,戴启明,丁建东,沈吉梅

• 1: 东南大学附属中大医院心脏科
• 2:东南大学附属中大医院心脏科
• 3:东南大学附属中大医院心脏科
• 4:东南大学附属中大医院心脏科

摘要(Abstract)：

目的评价高龄(≥70岁)非ST段抬高急性冠状动脉综合征(ACS)患者冠状动脉介入治疗(PCI)中应用国产血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班的安全性和近期疗效。方法108例行PCI的非ST段抬高ACS患者按年龄分为高龄组(≥70岁,42例)和非高龄组(<70岁,66例),分析两组基础资料特征、即刻手术成功率、出血和血小板减少发生率;观察住院和随访30天期间不良心血管事件(再发心绞痛、心肌梗死、心力衰竭及猝死)。结果高龄组甘油三酯、脂蛋白a高于非高龄组,体重指数和吸烟比例低于非高龄组(P均<0.05);高龄组多支病变比例高于非高龄组(71%比39%,P<0.01);两组PCI即刻成功率均为100%。高龄组发生小出血5例、血小板减少6例;非高龄组小出血2例,血小板减少2例;两组均无大出血发生。高龄组血小板减少及总副反应发生率高于非高龄组(P均<0.05),小出血发生率差异无统计学意义(P>0.05)。高龄组住院和随访期间再发心绞痛5例、心肌梗死1例、心力衰竭2例、猝死0例;非高龄组再发心绞痛7例、心力衰竭1例,无心肌梗死和猝死。两组间复合心血管事件发生率差异无统计学意义(P>0.05)。结论高龄非ST段抬高ACS患者PCI中应用国产替罗非班是安全的。

关键词(KeyWords)： 冠状动脉疾病;替罗非班;治疗结果

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈忠,马根山,冯毅,罗丹,沈成兴,戴启明,丁建东,沈吉梅

参考文献(References)：

• [1]The Platelet Receptor Inhibition In Ischemic Syndrome Management(PRISM)Study Investigators.Acomparision of aspirin plus tirofiban with aspirin plus heparinfor unstable angina.NEngl J Med,1998,338:1498-1505.
• [2]The PRISM-PLUS study investigators.Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.New Engl J Med,1998,338:1488-1497.
• [3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛诊断和治疗建议.中华心血管病杂志,2000,28:409-412.
• [4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会,中国循环杂志编辑委员会.急性心肌梗死诊断和治疗指南.中华心血管病杂志,2001,29:710-725.
• [5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南.中华心血管病杂志,2002,30:707-718.
• [6]血脂异常防治对策专题组.血脂异常防治建议.中华心血管病杂志,1997,25:169-175.
• [7]Bovill EG,Terrin ML,Stump DC,et al for the TIMI investigators.Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator,heparin and aspirin for acute myocardial infarction.Ann Intern Med,1991,115:256-265.
• [8]Braunwald E,Antman EM,Beasley JW,et al.American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee on the Management of Patients With Unstable Angina).ACC/AHAguideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002:summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee on the Management of Patients With Unstable Angina).Circulation,2002,106:1893-1900.
• [9]Huynh T,Piazza N,DiBattiste PM,et al.Analysis of bleeding complications associated withglycoproteinⅡb/Ⅲareceptors blockade in patients with high-risk acute coronarysyndromes:insightsfromthe PRISM-PLUS study.Int J Cardiol,2005,100:73-78.
• [10]Yilmaz MB,Akin Y,Biyikoglu SF,et al.Diffuse alveolar hemorrhage followingadministrationof tirofibanina patient withacute coronarysyndrome:afatal complication.Int J Cardiol,2004,93:81-82.
• [11]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.AmJ Cardiol,2004,93:280-287.
• [12]Gibson M,Singh KP,Murphy SA,et al.Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion(a TACTICS-TIMI18substudy).AmJ Cardiol,2004,94:492-494.
• [13]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction.JAMA,2005,293:2109-2117.